
News|Videos|August 1, 2024
Generics and Biosimilars in Multiple Sclerosis
Key opinion leaders explore the impact of newly available biosimilars and generic biologics for managing multiple sclerosis (MS), discussing how these developments have altered patient access to treatments and the implications for the future of the MS treatment landscape.
Advertisement
Episodes in this series

- Generics or biosimilar versions of many MS treatments are now available.
- How has this changed access to MS treatment for patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Apitegromab for Spinal Muscular Atrophy
2
AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs
3
Exploring the Link Between Football Players and ALS: Rory Siegel, DO
4
FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug
5







